Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Stock Information for Spero Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Spero Therapeutics Inc.

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
Spero Therapeutics to Present at Upcoming September Investor Conferences
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.